V-Go® is Proven to Significantly Reduce A1C
Across Adult Patients with Diabetes Requiring Insulin1-9
Switching to V-Go from prior glucose lowering therapies reduced mean A1C by 1.8% at 6 months1
Switching to V-Go from prior therapies including prescribed insulin decreased mean prescribed insulin by 36%1
Data from a restrospective study in 153 patients with diabetes with a mean A1C of 9.7% before switching to V-Go.
Prior therapies included a prescription of at least one of the following: basal insulin, bolus insulin, GLP-1 RA, or oral glucose lowering medication.1
References: 1. Lajara R, Nikkel C. Poster Presented at ACCE. May 2015. 2. Sutton D, Higdon C, Nikkel C, Hilsinger K. Advances in Therapy. May 2018. 3. Lajara R, Fetchick DA, Morris TL, Nikkel CN. Diabetes Ther. Oct 2015. 4. Everitt B, Harrison HC Jr, Nikkel C, Laswell E, Chen AMH. Sept 2019. 5. Grunberger G, Rosenfeld CR, Bode BW, Abbott SD, Nikkel C, Shi L, Strange P. Drugs Real World Outcomes. Mar 2020. 6. Hundal R, Kowalyk S, Wakim A, Nikkel C, Sink Ii JH, Doyle M. Sep 2020. 7. Zeidan T, Nikkel C, Dziengelewski B, Wu S, Chen AMH. Pharmacy. Nov 2020. 8. Rosenfeld CR, Bohannon NJ, Bode B, Kelman AS, Mintz SN, Schorr AB, Sandberg MI, Nambi S, Agarwala SK, Leichter SB, Larrabee B, Shi L, Strange P. Sept Endocr Pract. 2012. 9. Lajara R, Davidson JA, Nikkel CC, Morris TL. Endocr Pract Jun 2016. 10. Instructions for Patient Use. ART-1361 Rev D V-Go IFU 2023.
US-VGO-0102